{"title":"PPY-fMWCNT Nanocomposite-Based Chemicapacitive Biosensor for Ultrasensitive Detection of TBI-Specific GFAP Biomarker in Human Plasma","authors":"Patta Supraja;Rahul Gangwar;Suryasnata Tripathy;Siva Rama Krishna Vanjari;Shiv Govind Singh","doi":"10.1109/LSENS.2024.3497003","DOIUrl":null,"url":null,"abstract":"Traumatic brain injury (TBI) is physical damage to the brain and a significant cause of mortality and morbidity affecting all ages worldwide, remaining as a diagnostic and therapeutic challenge to date. The design and development of rapid, low cost, highly accurate, and long-term stable point-of-care TBI diagnostic test kits is an unmet clinical need. In light of this, here we report a novel multianalyte chemicapacitive immunosensing platform that can detect FDA-approved Glial Fibrillary Acidic Protein (GFAP) biomarkers in real-time human plasma samples using carboxylic functionalized MWCNTs (fMWCNTs) embedded Polypyrrole (PPY) as a bioelectrical transducer. Herein, the low-cost GFAP bioelectrodes were prepared through covalent immobilization of anti-GFAP-antibodies on PPY-fMWCNTs modified array of interdigitated microelectrodes (IDµEs, fabricated on low-cost single-side copper clad PCB substrates). The binding event of GFAP peptides with anti-GFAP-antibodies in real-time human plasma samples was captured in terms of ac capacitance measured through C-F analysis (using an Agilent B1500A parametric analyzer) and quantified in terms of normalized change in capacitance of GFAP bioelectrodes with and without exposure of target GFAP peptides spiked in real-time human plasma samples (10 fg/mL – 1 µg/mL). The proposed PPY-fMWCNTs nanocomposite-based chemicapacitive immunosensing platform effectively detected GFAP target analytes in linear detection range 10 fg/mL – 10 ng/mL with a sensitivity and LoD of 3.9743 ((ΔC/C\n<sub>0</sub>\n)/ng·mL\n<sup>−1</sup>\n)/cm\n<sup>2</sup>\n and 0.3854 fg/mL, respectively. Further, it also showed superior performance in terms of selectivity, reproducibility, long-term stability (30 weeks) and interference resistance. The proposed ac-capacitive approach is facile, label-free and can be combined with dc-resistive measurements to improve the diversity of decision-making parameters that inherently aid in improving the diagnostic accuracy of TBI test kit.","PeriodicalId":13014,"journal":{"name":"IEEE Sensors Letters","volume":"8 12","pages":"1-4"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IEEE Sensors Letters","FirstCategoryId":"1085","ListUrlMain":"https://ieeexplore.ieee.org/document/10753623/","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Traumatic brain injury (TBI) is physical damage to the brain and a significant cause of mortality and morbidity affecting all ages worldwide, remaining as a diagnostic and therapeutic challenge to date. The design and development of rapid, low cost, highly accurate, and long-term stable point-of-care TBI diagnostic test kits is an unmet clinical need. In light of this, here we report a novel multianalyte chemicapacitive immunosensing platform that can detect FDA-approved Glial Fibrillary Acidic Protein (GFAP) biomarkers in real-time human plasma samples using carboxylic functionalized MWCNTs (fMWCNTs) embedded Polypyrrole (PPY) as a bioelectrical transducer. Herein, the low-cost GFAP bioelectrodes were prepared through covalent immobilization of anti-GFAP-antibodies on PPY-fMWCNTs modified array of interdigitated microelectrodes (IDµEs, fabricated on low-cost single-side copper clad PCB substrates). The binding event of GFAP peptides with anti-GFAP-antibodies in real-time human plasma samples was captured in terms of ac capacitance measured through C-F analysis (using an Agilent B1500A parametric analyzer) and quantified in terms of normalized change in capacitance of GFAP bioelectrodes with and without exposure of target GFAP peptides spiked in real-time human plasma samples (10 fg/mL – 1 µg/mL). The proposed PPY-fMWCNTs nanocomposite-based chemicapacitive immunosensing platform effectively detected GFAP target analytes in linear detection range 10 fg/mL – 10 ng/mL with a sensitivity and LoD of 3.9743 ((ΔC/C
0
)/ng·mL
−1
)/cm
2
and 0.3854 fg/mL, respectively. Further, it also showed superior performance in terms of selectivity, reproducibility, long-term stability (30 weeks) and interference resistance. The proposed ac-capacitive approach is facile, label-free and can be combined with dc-resistive measurements to improve the diversity of decision-making parameters that inherently aid in improving the diagnostic accuracy of TBI test kit.